Fortress Biotech Inc expected to post a loss of $1.97 a share - Earnings Preview

Fortress Biotech

26/03/2024 11:02

* Fortress Biotech Inc  FBIO.OQ   FBIO.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 28
(estimated) for the period ending December 31 2023
    * The Bay Harbor Islands Florida-based  company is expected
to
report a 9.2% decrease in revenue to $14.894 million from $16.4
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fortress Biotech Inc is
for a
loss of $1.97 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fortress
Biotech
Inc is $10.00​, above​ its last closing price of $1.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -3.12       -3.21      -0.94     Beat    70.7
 Jun. 30 2023  -3.31       -3.41      -3.60     Missed  -5.5
 Mar. 31 2023  -3.38       -3.00      -3.15     Missed  -5​
 Dec. 31 2022  -3.43       -3.37      -4.46     Missed  -32.2
 ​​Sep.        -3.18       -4.05      -3.75     Beat    7.4
 30 2022                                                
 Jun. 30 2022  -3.28       -3.15      -3.60     Missed  -14.3​
 Mar. 31 2022  -3.97       -4.20      -2.70     Beat    35.7
 Dec. 31 2021  -2.10       2.64       -5.70     Missed  -315.9
 This summary was machine generated March 26 at 11:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)